210891-15-9Relevant academic research and scientific papers
ENDOTHELIN ANTAGONISTS: N- 2'- (4,5-DIMETHYL-3-ISOXAZOLYL) AMINO]SULFONYL]-4-(2-OXAZOLYL) 1,1'-BIPHENYL]-2-YL]METHYL] -N,3,3-TRIMETHYLBUTANAMIDE AND N-(4,5-DIMETHYL-3-ISOXAZOLYL) -2'- (3,3-DIMETHYL-2-OXO-1-PYRROLIDINYL) METHYL] -4'-(2-OXAZOLYL) 1,1'-BIPHE
-
Page/Page column 9, (2010/02/03)
The compounds N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfon
Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2′-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4- (2-oxazolyl)[1,1′-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ETA s
Murugesan, Natesan,Gu, Zhengxiang,Spergel, Steven,Young, Marian,Chen, Ping,Mathur, Arvind,Leith, Leslie,Hermsmeier, Mark,Liu, Eddie C.-K.,Zhang, Rongan,Bird, Eileen,Waldron, Tom,Marino, Anthony,Koplowitz, Barry,Humphreys, W. Griffith,Chong, Saeho,Morrison, Richard A.,Webb, Maria L.,Moreland, Suzanne,Trippodo, Nick,Barrish, Joel C.
, p. 125 - 137 (2007/10/03)
We have previously disclosed the selective ETA receptor antagonist N-(3,4-dimethyl-5-isoxazolyl)-4′-(2-oxazolyl)[1,1′- biphenyl]-2-sulfonamide (1, BMS-193884) as a clinical development candidate. Additional SAR studies at the 2′-position of 1 l
